The agency says it assessed corrective and preventive actions taken after its 22 July decision. The list includes presentations of Flustaph, Torva and Dispamox, together with Roxam and Agiderm. Arthrodont Classic is the health product concerned.
The decision addresses the regulatory status of the listed products; the notice does not provide a pharmacy restocking timetable.